CH621338A5 - - Google Patents

Download PDF

Info

Publication number
CH621338A5
CH621338A5 CH345775A CH345775A CH621338A5 CH 621338 A5 CH621338 A5 CH 621338A5 CH 345775 A CH345775 A CH 345775A CH 345775 A CH345775 A CH 345775A CH 621338 A5 CH621338 A5 CH 621338A5
Authority
CH
Switzerland
Prior art keywords
pyrrolidone
prepared
phenyl
methoxyphenyl
methoxy
Prior art date
Application number
CH345775A
Other languages
German (de)
English (en)
Inventor
Ralph Dr Schmiechen
Reinhard Dr Horowski
Dieter Dr Palenschat
Gert Dr Paschelke
Helmut Dr Wachtel
Wolfgang Dr Kehr
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CH621338A5 publication Critical patent/CH621338A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/52Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CH345775A 1974-03-20 1975-03-18 CH621338A5 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2413935A DE2413935A1 (de) 1974-03-20 1974-03-20 4-(polyalkoxy-phenyl)-2-pyrrolidone

Publications (1)

Publication Number Publication Date
CH621338A5 true CH621338A5 (da) 1981-01-30

Family

ID=5910915

Family Applications (1)

Application Number Title Priority Date Filing Date
CH345775A CH621338A5 (da) 1974-03-20 1975-03-18

Country Status (20)

Country Link
US (1) US4012495A (da)
JP (1) JPS6011028B2 (da)
AT (1) AT347931B (da)
BE (1) BE826923A (da)
CA (1) CA1069517A (da)
CH (1) CH621338A5 (da)
CS (1) CS214738B2 (da)
DD (1) DD119229A5 (da)
DE (1) DE2413935A1 (da)
DK (1) DK139965C (da)
ES (1) ES435750A1 (da)
FR (1) FR2264531B1 (da)
GB (1) GB1498705A (da)
HU (1) HU174074B (da)
IE (1) IE40865B1 (da)
IL (1) IL46883A (da)
NL (1) NL7503367A (da)
SE (1) SE402010B (da)
SU (1) SU649312A3 (da)
YU (1) YU40258B (da)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
CU21107A3 (es) * 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
IL57266A (en) 1978-06-12 1982-12-31 Mundipharma Ag Production of pyrrolidin-2-ones and of 3-pyrrolin-2-ones
IT1131959B (it) * 1979-08-09 1986-06-25 Hoffmann La Roche Derivati pirrolidinici
GB2123288A (en) * 1982-07-16 1984-02-01 Wellcome Found Anti-thrombotic agent
US4584313A (en) * 1984-05-07 1986-04-22 Warner-Lambert Company (Substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids and esters thereof, and use for reversing electroconvulsive shock-induced amnesia
US4548947A (en) * 1984-05-07 1985-10-22 Warner-Lambert Company 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia
US5783591A (en) * 1984-10-19 1998-07-21 Schering Aktiengesellschaft Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US5459145A (en) * 1988-01-19 1995-10-17 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
FI875101A (fi) * 1986-12-03 1988-06-04 Tanabe Seiyaku Co Laktamderivat och preparat innehaollande dessa.
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US4960457A (en) * 1988-12-27 1990-10-02 Ici Americas Inc. Substituted 1,3-diphenyl pyrrolidones and their use as herbicides
DD295358A5 (de) * 1989-06-28 1991-10-31 �����@������������������k�� Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-estern
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
DE3943385A1 (de) * 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
DD299058A5 (de) * 1990-01-31 1992-03-26 Arzneimittelwerk Dresden Gmbh,De Verfahren zur herstellung von n-acyl-4-phenyl-pyrrolidin-2-onen mit cerebroprotektiver wirkung
GB9009395D0 (en) * 1990-04-26 1990-06-20 Orion Yhtymae Oy Cyclic hydroxamic acids and their use
ATE161720T1 (de) * 1990-08-03 1998-01-15 Smithkline Beecham Corp Tnf-inhibitoren
DE4032055A1 (de) * 1990-10-05 1992-04-09 Schering Ag Verfahren zur herstellung von optisch aktiven 4-aryl-2-pyrrolidinonen
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
US5395935A (en) * 1992-05-08 1995-03-07 Pfizer Inc. Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5477611A (en) * 1993-09-20 1995-12-26 Tessera, Inc. Method of forming interface between die and chip carrier
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
CA2143143A1 (en) * 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
US5338739A (en) * 1994-03-10 1994-08-16 Hoechst-Roussel Pharmaceuticals Inc. (Pyrrolidinyl)phenyl carbamates, compositions and use
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10508032A (ja) 1994-12-13 1998-08-04 ユーロ−セルティーク,エス.エイ. アリールチオキサンチン類
US6025361A (en) 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
HUP9702408A3 (en) * 1995-02-10 2000-08-28 Schering Ag Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
JP4017214B2 (ja) 1996-06-11 2007-12-05 興和創薬株式会社 5−フェニル−3−ピリダジノン誘導体
US6251897B1 (en) 1996-07-31 2001-06-26 Nikken Chemicals Co., Ltd 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same
CA2264685C (en) 1996-08-27 2002-10-15 Kyoji Noda 2-phenylmorpholin-5-one derivatives and pharmaceutical composition comprising the same
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
WO2001013953A2 (en) 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US6235736B1 (en) 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
JP3956188B2 (ja) * 1999-05-11 2007-08-08 三菱化学株式会社 プリン誘導体2水和物、それを有効成分として含む医薬およびその製造中間体
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
WO2001070746A1 (fr) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derives de furoisoquinoleine, leur procede de production et leur utilisation
CA2449118A1 (en) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ATE476173T1 (de) * 2001-07-16 2010-08-15 Merck Patent Gmbh Photostabile organische sonnenschutzmittel mit antioxidativen eigenschaften
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
JP4484515B2 (ja) * 2001-10-16 2010-06-16 メモリ ファーマセチカル コーポレーション 神経病症候群の治療の為のpde−4阻害剤としての、4−(4−アルコキシ−3−ヒドロキシフェニル)−2−ピロリディン誘導体。
AU2003234716A1 (en) * 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
WO2004011470A1 (ja) * 2002-07-26 2004-02-05 Takeda Pharmaceutical Company Limited フロイソキノリン誘導体およびその用途
US7495016B2 (en) * 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
SG169900A1 (en) * 2003-04-16 2011-04-29 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
JP2006523719A (ja) * 2003-04-18 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ4抑制剤としてのピラゾール誘導体
EP1618089A1 (en) * 2003-04-25 2006-01-25 Icos Corporation Method of preparing a ring compound having two adjacent chiral centers
MXPA06013305A (es) * 2004-05-17 2007-02-02 Otsuka Pharma Co Ltd Compuesto de tiazol y uso del mismo.
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
AU2005295753A1 (en) 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
JP2008517066A (ja) * 2004-10-20 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ4阻害剤
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20100159034A1 (en) * 2008-12-15 2010-06-24 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2681236B1 (en) 2011-03-01 2018-01-03 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516776A (fr) 1966-07-21 1968-03-15 Rhone Poulenc Sa Nouveaux dérivés du pyrrole et leur préparation
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone

Also Published As

Publication number Publication date
ATA210975A (de) 1978-06-15
IE40865L (en) 1975-09-20
NL7503367A (nl) 1975-09-23
JPS6011028B2 (ja) 1985-03-22
DD119229A5 (da) 1976-04-12
IL46883A (en) 1979-09-30
FR2264531A1 (da) 1975-10-17
GB1498705A (en) 1978-01-25
JPS50157360A (da) 1975-12-19
FR2264531B1 (da) 1978-07-28
DK110675A (da) 1975-09-21
AT347931B (de) 1979-01-25
SE402010B (sv) 1978-06-12
YU63275A (en) 1982-06-30
YU40258B (en) 1985-10-31
DE2413935C2 (da) 1988-05-26
ES435750A1 (es) 1976-12-16
BE826923A (fr) 1975-09-22
SE7503157L (sv) 1975-11-28
CA1069517A (en) 1980-01-08
AU7931075A (en) 1976-09-23
DK139965C (da) 1979-10-29
IE40865B1 (en) 1979-08-29
SU649312A3 (ru) 1979-02-25
DK139965B (da) 1979-05-28
IL46883A0 (en) 1975-05-22
CS214738B2 (en) 1982-05-28
HU174074B (hu) 1979-10-28
US4012495A (en) 1977-03-15
DE2413935A1 (de) 1975-10-16

Similar Documents

Publication Publication Date Title
CH621338A5 (da)
DE2541855A1 (de) 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
DD207713A1 (de) Substituierte imidazolabkoemmlinge, ihre herstellung und verwendung
DE2755752A1 (de) Piperazinderivate, verfahren zu ihrer herstellung und ihre verwendung
DE2716943A1 (de) Organische verbindungen, ihre verwendung und herstellung
DE1795841C3 (de) H2'-Chlor)-benzyl-2-di-sec.-butylamino-acetyl-pyrrol, seine Salze und Verfahren zu deren Herstellung
DE2044172A1 (de) Neue Pyrroldenvate, ein Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittelzubereitungen
DE1770372A1 (de) Neue Indolinderivate und Verfahren zu ihrer Herstellung
DE2332707A1 (de) Tricyclische tetrahydronaphthalinderivate, ihre salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CH628048A5 (de) Verfahren zur herstellung neuer benzopyron-derivate.
DE1104965B (de) Verfahren zur Herstellung von Derivaten des Urazols
DE3520104A1 (de) Naphthoxazine, ihre herstellung und verwendung
DE2914166A1 (de) Arylsubstituierte furane und verfahren zu ihrer herstellung
DE1695963A1 (de) Cycloalkenamin-p-benzochinonaddukte und Verfahren zu ihrer Herstellung
DE2838276A1 (de) Beta -substituierte diketone, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE2509797C2 (de) Phthalimidine, deren physiologisch verträgliche Säureadditionssalze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE1618643A1 (de) Aryloxysubstituierte Carbonsaeuren und Verfahren zu deren Herstellung
EP0000013A1 (de) 4-Phenyl-8-amino-tetrahydroisochinoline, diese enthaltende pharmazeutische Präparate und Verfahren zur Herstellung dieser Präparate
DE1543250A1 (de) Naphthyloxyalkansaeuren und Verfahren zu ihrer Herstellung
DE3003323A1 (de) 4-amino-2-piperidinochinazolin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel
AT338811B (de) Verfahren zur herstellung von neuen 2-amino-5-sulfamoylbenzoesaureamiden und ihren salzen sowie optischen isomeren
DE2740852A1 (de) Basische 1-acylindol-3-acetocyessigsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AT253485B (de) Verfahren zur Herstellung von neuen Acrylylnaphthyloxymonocarbonsäuren und deren Derivaten
AT334341B (de) Verfahren zur herstellung von neuen alpha- (1-bis-arylalkylaminoalkyl) -aralkoxybenzylalkoholen
CH634313A5 (en) Piperazine derivatives

Legal Events

Date Code Title Description
PL Patent ceased